ArticleOncology letters2020
Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam.Cancer management and research · 2025Article
- Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.Molecules (Basel, Switzerland) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficacy of trastuzumab, carboplatin and docetaxel in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer patients was investigated. A total of 180 HER-2-positive breast cancer patients admitted to The First People's Hospital of Yunnan Province were selected, of which 80 patients were treated with carboplatin and docetaxel and served as the control group (CG), and 100 patients were treated with trastuzumab, carboplatin and docetaxel and served as the research group (RG). Clinical efficacy, pathological efficacy, adverse reactions, inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), cellular immune indexes of T-lymphocyte subsets (CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.